Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 4,170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Completed Phase 2 Interventional

Study of Focal Cryoablation in Low-Risk Prostate Cancer

NCT00774436
View directory record Official record
Conditions
Prostate Cancer
Interventions
focal cryotherapy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 28, 2026, 7:58 PM EDT
Withdrawn Early Phase 1 Interventional

Insulin Resistance Following ADT for Prostate CA

NCT04658849
View directory record Official record
Conditions
Insulin Resistance, Prostate Cancer
Interventions
Pioglitazone 30 Mg Oral Tablet, Pioglitazone placebo tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 28, 2026, 7:58 PM EDT
Terminated No phase listed Observational

MRI Before Biopsy in Diagnosing Patients With Prostate Cancer

NCT02131207
View directory record Official record
Conditions
Prostate Cancer
Interventions
magnetic resonance imaging, prostate biopsy
Device · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 2 Interventional Results available

Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer

NCT00715104
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sipuleucel-T with Booster, Sipuleucel-T without Booster
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 28, 2026, 7:58 PM EDT
Active, not recruiting No phase listed Observational

Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer

NCT03957252
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Screening, Performance Assessment of Novel Test
Interventions
Not listed
Lead sponsor
Nanostics
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03724747
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
BAY2315497 Injection, Darolutamide(BAY1841788)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
New Orleans, Louisiana • Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 28, 2026, 7:58 PM EDT
Withdrawn Phase 1 Interventional

Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer

NCT01163448
View directory record Official record
Conditions
Prostate Cancer
Interventions
High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 28, 2026, 7:58 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

NCT02768363
View directory record Official record
Conditions
Prostate Cancer
Interventions
aglatimagene besadenovec, placebo, valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Golden, Colorado • Chicago, Illinois • New Orleans, Louisiana + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 2 Interventional Results available

Satraplatin and Prednisone to Treat Prostate Cancer

NCT00634647
View directory record Official record
Conditions
Prostate Cancer, Genetic Polymorphism
Interventions
Satraplatin, prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 2 Interventional Results available

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

NCT02217709
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
phenelzine sulfate, laboratory biomarker analysis, questionnaire administration
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

NCT00215709
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
Geriatric Oncology Consortium
Other
Eligibility
65 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Oct 28, 2026, 7:58 PM EDT
Terminated Phase 2 Interventional

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

NCT05676463
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, Biospecimen Collection, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 28, 2026, 7:58 PM EDT
Terminated Phase 2 Interventional

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

NCT05689021
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Prednisone
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

NCT02572284
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), Prostatectomy, Quality of Life Questionnaires
Radiation · Procedure · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 28, 2026, 7:58 PM EDT
Completed No phase listed Observational

Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data

NCT00341939
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma, Lung Cancer, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

NCT03016312
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Atezolizumab, Enzalutamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Male only
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
39
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 28, 2026, 7:58 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

NCT02685267
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Enzalutamide, Prednisone
Drug
Lead sponsor
Prostate Cancer Clinical Trials Consortium
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

NCT00331344
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
mitoxantrone hydrochloride, ixabepilone, prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 28, 2026, 7:58 PM EDT
Terminated No phase listed Observational

Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

NCT06655064
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
None- Observational
Other
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
9
States / cities
Fresno, California • Grand Junction, Colorado • Meridian, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 28, 2026, 7:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

NCT04422132
View directory record Official record
Conditions
Prostate Cancer
Interventions
5 days Radiation Therapy (32.5 Gy in 5 fractions), 20 days Radiation therapy (55 Gy in 20 fractions)
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 7:58 PM EDT
Completed No phase listed Observational

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

NCT03857087
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 28, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer

NCT00882232
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cross-linked hyaluronan gel
Device
Lead sponsor
Cancer Center of Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 28, 2026, 7:58 PM EDT
Terminated Phase 1 Interventional Results available

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

NCT03478904
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide Liquid, Enzalutamide Capsule
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 28, 2026, 7:58 PM EDT
Recruiting Phase 1 Interventional

Two Fraction Prostate SBRT With DIL SIB

NCT05864196
View directory record Official record
Conditions
Prostate Cancer
Interventions
Two-Fraction Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Mineola, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 28, 2026, 7:58 PM EDT